Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The SPYRAL AFFIRM study — the largest US trial of radiofrequency renal denervation — showed the procedure significantly cut systolic blood pressure by 18.2 mm Hg at 6 months without requiring more medication. Nearly 9 in 10 patients saw meaningful clinical benefit. The results strengthen the case for this FDA-approved device as a viable option for patients with uncontrolled hypertension.
A major new trial is giving radiofrequency renal denervation — a catheter-based procedure that disrupts nerve signals around the kidney to lower blood pressure — its strongest US endorsement yet. The SPYRAL AFFIRM study, presented at TCT 2026, enrolled 594 patients with uncontrolled hypertension across 89 international centers. At baseline, patients were already on an average of 3.6 antihypertensive medications, yet their blood pressure remained dangerously elevated.
After 6 months, the Symplicity Spyral device (Medtronic) reduced average office systolic BP by 18.2 mm Hg — far exceeding the prespecified performance goal of 6 mm Hg. Home and 24-hour blood pressure readings also dropped by roughly 9 mm Hg each, and medication burden stayed flat throughout the study. Benefits were consistent across diverse subgroups including Black patients, women, older adults, and those with diabetes or chronic kidney disease.
Key Takeaways:
Why it matters: Millions of patients struggle with hypertension that doesn't respond adequately to medication. This trial offers compelling evidence that renal denervation can provide meaningful, drug-free blood pressure relief — potentially reshaping how uncontrolled hypertension is managed.